【摘要】 目的 探討經尿道超脈沖等離子體腔內逆行剜除汽化切除術治療良性前列腺增生的有效性和安全性。 方法 2008年4月－2009年4月，應用Gyrus超脈沖等離子體行經尿道前列腺腔內逆行剜除汽化切除術124例，前列腺重量為（62.3±21.7） g。術中首先用電切鏡鞘、電切環鈍銳性相結合將前列腺增生腺體沿外科包膜逆行剝離、剜除，同時斷血供，然后推至膀胱頸處后切除。統計手術時間、術中出血量及收集到的前列腺組織質量，術后留置尿管時間、住院時間、手術后前列腺特異性抗原（prostatic specific antigen，PSA）、殘余尿量（post voiding residual volume，PVR）、最大尿流率（Qmax）、國際前列腺癥狀評分（international prostatic symptom scores，IPSS）及生活質量評分（quality of life，QOL）等指標的變化。 結果 124例手術順利完成。手術時間（48.1±19.4） min，腺體組織質量（57.6±19.6） g，平均失血量（86.2±20.7） mL，僅1例需要輸血，出血量和手術時間隨前列腺體積和重量的增加而相應增加和延長。術后留置尿管時間（3.1±1.6） d，住院時間（5.8±1.4） d。隨訪6～18個月，所有患者術后1、6個月Qmax、PVR、IPSS、QOL均較術前得到改善，與術前比較差異均有統計學意義（Plt;0.05）。術后6個月血清PSA降至（0.90±0.26） ng/mL，與術前比較差異有統計學意義（Plt;0.05）。繼發尿道外口狹窄3例，經尿道擴張治療后恢復排尿通暢；繼發尿失禁2例，經保守治療分別于術后1～6個月恢復；無永久性尿失禁、再次手術止血患者，無手術死亡者，未發生經尿道前列腺電切綜合征。 結論 經尿道超脈沖等離子體腔內逆行剜除汽化切除術治療良性前列腺增生安全有效，值得臨床推廣使用。【Abstract】 Objective To evaluate the safety and clinical efficacy of superpulse plasmakinetic body in transurethral intracavitary retrograde enucleation and vaporization resection of the prostate (TUEVRP) for the treatment of benign prostatic hyperplasia (BPH). Methods Between April 2008 and April 2009, Gyrus TUEVRP was performed on 124 patients with obstructive BPH whose mean prostatic weight was (62.3±21.7) g. The hyperplasia prostate glands were retrogradely dissected and enucleated along surgical capsule to the bladder neck by sharp and blunt dissection combination of the resectoscope tip or loop. Simultaneously, the blood supply of the gland was clamped. The changes of such indexes as operating time, perioperative blood loss, collected prostatic specimen weight, postoperative catheterization time, hospitalization time, prostatic specific antigen (PSA), post voiding residual volume (PVR), maximum urinary flow rate (Qmax), international prostatic symptom score (IPSS), and quality of life (QOL) were assessed. Results All surgeries were successfully carried out with an average operation time of (48.1±19.4) minutes ranged from 25 to 175 minutes. The mean collected prostatic specimen weight was (57.6±19.6) g ranged from 20.2 to 125.7 g. The blood loss was ranged from 45 to 350 ml, averaging at (86.2±20.7) mL during the operation. Blood transfusion was needed in only one case. Blood loss and operation time were increased and prolonged in accordance with the increase of prostatic volume and weight. The postoperative catheterization time was ranged from 2 to 5 days, averaging at 3.1±1.6. The mean hospitalization time was (5.8±1.4) days ranged from 5 to 8 days. All patients were followed up for 6 to 18 months. Qmax, PVR, IPSS and QOL-score six months after operation were significantly improved compared with those before operation (Plt;0.05). There were three cases of external urethral stricture, and they were treated with urethral dilatation successfully. Two cases of urinary incontinence recovered 1 and 6 months later, respectively, by traditional treatment. There were no cases of permanent urinary incontinence, reoperation for hemostasis, operative death, or transurethral resection syndrome. Conclusion TUEVRP is safe and clinically efficacious in the treatment of BPH, and is worthy of clinical promotion.
目的 探討前列腺體積＞60 mL的前列腺增生癥患者的手術安全性，提高部分合并尿道狹窄前列腺增生癥患者的手術實施率。 方法 2009年3月－2010年3月，行恥骨上膀胱穿刺引流下經尿道前列腺電切術（TURP）治療前列腺增生58例。年齡54～93歲，平均72歲，病程8個月～12年，平均7.2年；前列腺體積35～128 mL，平均78 mL；國際前列腺癥狀評分24～35分，平均30.2分 ；最大尿流率1.2～4.8 mL/s，平均1.8 mL/s；殘余尿量84～210 mL，平均160 mL。術前無尿潴留28例。 結果 58例順利完成手術，其中2例伴包膜穿孔，9例前尿道狹窄者通過去外鞘電切鏡完成手術。所有患者切除前列腺組織體積18～86 mL，平均58 mL；術中沖洗液為5%葡萄糖液，用量18 600～42 500 mL，平均23 500 mL；手術時間45～185 min，平均70 min。術后病理檢查均示良性前列腺增生，術后住院時間3～8 d，平均5 d。術后患者最大尿流率為18～46 mL/s，平均32 mL/s。 結論 恥骨上膀胱穿刺引流能降低膀胱內壓，減少水、糖分吸收，增加手術安全性，提高了部分合并前尿道狹窄的前列腺增生患者的手術幾率。
目的:探討良性前列腺增生癥（benign prostatic hyperplasia，BPH）應用單極電切（TURP）經尿道前列腺剜除術的方法及療效。方法：應用普通單極電切設備，采用經尿道前列腺剜除術治療良性前列腺增生癥患者21例。并對患者術前、術后的國際前列腺癥狀評分、生活質量評分進行比較。結果：全部患者均順利完成手術，切除前列腺重量平均45 g，平均手術時間90 min，術后平均留置導尿管5~7天，術后平均住院時間5.5天。術后前列腺癥狀評分（IPSS）平均減少24分，生活質量評分平均減少3分。結論：經尿道單極電切前列腺剜除術治療BPH安全、有效、并發癥少，所需設備價格較低，特別適合基層醫院開展，是一種值得推廣的方法。
Objective To objectively evaluate the efficacy and safety of plasmakinetic enucleation for prostate (PKEP) vs plasmakinetic resection for prostate (PKRP) in treating benign prostate hyperplasia (BPH). Methods Such databases as PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), EMbase, the ISI Web of Knowledge databases, VIP, CNKI, CBM and Wanfang were searched from their establishment to March 2011 for collecting the randomized controlled trials (RCTs) about PKEP vs PKRP for the treatment of BPH, and the references of those RCTs were also searched by hand. After study selection, assessment and data extraction conducted by two reviewers independently, meta-analyses were performed by using the RevMan 5.1 software. The level of evidence was assessed by using the GRADE system. Results Eight studies involving 991 patients were included. The results of meta-analyses showed that: a) safety indicator: compared with the PKRP, PKEP had shorter operation time (SMD=1.07, 95%CI 0.19 to 1.94, P=0.02), less intraoperative bleeding (SMD=2.06, 95%CI 1.42 to 2.69, Plt;0.01), much quantity of resectable prostate (SMD= –0.91, 95%CI –1.33 to –0.48, Plt;0.000 1), less intraoperative perforation (RR=4.48, 95%CI 1.43 to 14.02, P=0.01), shorter catheterization time (SMD=1.98, 95%CI 0.39 to 3.57, P=0.01), shorter bladder irrigation time (SMD=3.49, 95%CI 0.51 to 6.47, P=0.02) and shorter hospital stay (SMD=0.89, 95%CI 0.64 to 1.13, Plt;0.01), but there was no significant difference in total postoperative complications (RR=0.82, 95%CI 0.54 to 1.24, P=0.35); and b) efficacy indicator: compared with the PKRP, the International Prostate Symptom Score (IPSS) was lower after 3 months, the Quality Of Life (QOL) was higher after 3 months, and the improvement of residual urine volume (RUV) was better after 6 months; but other efficacy indicators had no significant difference between the two groups (Pgt;0.05). Based on GRADE system, all the evidence was at level C and weak recommendation (2C). Conclusion The current evidence indicates that PKEP is similar to PKRP in the treating effect, but it resects the proliferated prostate more cleanly with shorter operation time, lesser bleeding and more safety than PKRP; for the poor quality of the original studies, a prudent choice is suggested; and more high-quality, large-sample studies are need.
目的:探討微創治療BPH并發膀胱結石的方法。方法:應用氣壓彈道碎石術聯合TURP治療BPH并發膀胱結石26例。結果:24例一次成功,1例一期碎石,二期行TURP;1例中轉開放手術。結論:氣壓彈道碎石術聯合TURP治療BPH并發膀胱結石創傷小,恢復快,安全高效。
【摘要】 目的 探討采用不同方法經尿道前列腺等離子雙極電切術（plasmakinetic resection of prostate，PKRP）的方法及療效。 方法 2008年7月-2009年12月，應用不同方法行PKRP治療156例前列腺增生。患者年齡59~87歲，平均74歲。病程20 d~18年。前列腺重量22~100 g，平均38 g。采用單純順行電切法治療38例，部分剜除分割切除法治療76例，完全剜除法治療42例。 結果 156例手術均獲成功，手術時間平均90 min。獲得前列腺組織12~87 g，平均35 g。術后留置導尿管平均5.5 d，住院時間平均6.5 d。術后組織病理學診斷為良性前列腺增生152例，前列腺癌4例。拔除尿管后均能自主排尿，部分患者術后有尿道刺激癥狀；術后1個月內出現尿道外口狹窄3例，經尿道擴張治愈。隨訪時間1~12個月，平均6個月。短期尿失禁3例，時間分別為1周、1個月及3個月；無長期尿失禁。術后3個月國際前列腺癥狀評分（IPSS）癥狀評分平均減少24分，生活質量評分平均減少3分。 結論 PKRP安全、有效、并發癥少，可針對患者情況采用不同切割方法，效果更佳。【Abstract】 Objective To explore the effects and methods of transurethral plasmakinetic resection of prostate(PKRP). Methods A total of 156 patients with prostatic hyperplasia were treated with various methods of transurethral PKRP from July 2008 to December 2009. Patient’s age ranged from 59 to 87 years,74 years on average. The disease duration was 20 days to 18 years.Method one:anterograde resection in 38 patients; method two:partition retrograde enucleation in 76 patients; method three:completely retrograde enucleation in 42 patients. Results All of the swgeries were successful. The mean duration of the operation was 90 minutes.The collected prostatic specimens were 12-87 g,35 g on average. The mean catheter remaining dwation was 5.5 days.The mean postoperative hospital stay was 6.5 days. Conclusions PKRP is safe and effective. It is effective with various methods of transurethral plasmakinetic resection of prostate.
Prostate disease is one of the most common urological disease. A large number of studies have shown that prostate disease is related to changes in the local microenvironment. Periodontitis is a chronic inflammatory disease characterized by the destruction of periodontal tissue caused by a variety of pathogenic microorganisms. Its pathogenesis may involve many factors. Periodontitis may have adverse effects on cardiovascular, respiratory, digestive and endocrine systems. Recent studies have found that chronic periodontitis is associated with the occurrence and development of benign prostatic hyperplasia and prostatitis, but the relationship is not clear. Therefore, further research is needed. This article elaborates on inflammation and benign prostatic hyperplasia and prostatitis, periodontitis and prostatitis, and periodontitis and benign prostatic hyperplasia, aiming to provide certain ideas for clinical research and diagnosis and treatment.